Research Scientists

Minhee Kang

Senior Research Scientist

Biostatistics

mkang@hsph.harvard.edu

Links

Catalyst Profile

Overview

Education and Training
Awards and Honors

Ph.D., Biostatistics
Harvard University, Cambridge, MA

Sc.B., Applied Mathematics
Brown University, Providence, RI

M.S., Operations Research
Cornell University, Ithaca, NY

Howard Hughes Medical Institute Predoctoral Fellowship in Biological Sciences1998-2003

Bibliography

Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings.

Epeldegui M, Chang D, Lee J, Magpantay LI, Borok M, Bukuru A, Busakhala N, Godfrey C, Hosseinipour MC, Kang M, Kanyama C, Langat D, Mngqibisa R, Mwelase N, Nyirenda M, Samaneka W, Hoagland B, Campbell TB, Martínez-Maza O, Krown SE.

J Acquir Immune Defic Syndr. 2023 10 01. 94(2):165-173. PMID: 37368929

Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV.

Kang M, Price JC, Peters MG, Lewin SR, Sulkowski M.

J Virus Erad. 2023 Sep. 9(3):100344. PMID: 37744732

Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.

Marks KM, Kang M, Umbleja T, Avihingsanon A, Sugandhavesa P, Cox AL, Vigil K, Perazzo H, Price JC, Katsidzira L, Vernon C, Alston-Smith B, Sherman KE.

Clin Infect Dis. 2023 08 14. 77(3):414-418. PMID: 37017075

Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS).

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG.

Open Forum Infect Dis. 2023 Mar. 10(3):ofad115. PMID: 37008564

Effects of Sex, Existing Antibodies, and HIV-1-Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV.

Kang M, Umbleja T, Ellsworth G, Aberg J, Wilkin T.

J Acquir Immune Defic Syndr. 2022 04 01. 89(4):414-422. PMID: 34907980

Incorporating estimands into clinical trial statistical analysis plans.

Kang M, Kendall MA, Ribaudo H, Tierney C, Zheng L, Smeaton L, Lindsey JC.

Clin Trials. 2022 06. 19(3):285-291. PMID: 35257600

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.

Hawkins C, Kang M, Bhattacharya D, Cloherty G, Kuhns M, Matining R, Thio C, Samaneka W, Chinula L, Mulinda N, Badal-Faesen S, Sugandhavesa P, Lama J, Gaseitsiwe S, Holzmayer V, Anderson M, Murphy R, Peters M.

AIDS. 2022 06 01. 36(7):975-984. PMID: 35165216

Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).

Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG.

Open Forum Infect Dis. 2021 Dec. 8(12):ofab511. PMID: 34926713

Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy.

Nyirenda M, Ngongondo M, Kang M, Umbleja T, Krown SE, Godfrey C, Samaneka W, Mngqibisa R, Hoagland B, Mwelase N, Caruso S, Martinez-Maza O, Dittmer DP, Borok M, Hosseinipour MC, Campbell TB.

J Acquir Immune Defic Syndr. 2020 08 01. 84(4):422-429. PMID: 32265361

Interim monitoring in a treatment strategy trial with a composite primary endpoint.

Kang M, Grund B, Hunsberger S, Glidden D, Volberding P.

Contemp Clin Trials. 2019 11. 86:105846. PMID: 31520741

VIEW MORE PUBLICATIONS